Azurity Pharmaceuticals

What Azurity Pharmaceuticals does

Azurity Pharmaceuticals is a privately held specialty pharmaceutical company headquartered in Woburn, Massachusetts, that develops and commercializes reformulated versions of established medicines for patient populations underserved by conventional dosage forms. The company's core technology is dose-form innovation — primarily ready-to-use oral liquids, oral suspensions, prefilled syringes, and injectable emulsions — developed through formulation science and brought to market via the FDA's 505(b)(2) regulatory pathway. Azurity's portfolio spans approximately 50 medicines across 10 therapeutic areas including cardiovascular, central nervous system, endocrinology, gastroenterology, oncology, and respiratory conditions, distributed in over 50 countries.

The company makes money through branded pharmaceutical product sales, in-licensing commercialization rights (e.g., exclusive U.S. rights to WIDAPLIK from George Medicines with milestone and royalty obligations), and licensing partnerships for international distribution (e.g., ACA Pharma for Asia-Pacific). The go-to-market model combines an enterprise field sales force targeting healthcare providers with the Azurity Solutions digital platform supporting Patient Direct and E-Z Rx patient access programs; marketing is anchored by Ogilvy Health as agency of record.

Azurity has grown principally through acquisition, completing deals for Silvergate Pharmaceuticals (2019), Arbor Pharmaceuticals (2021), Slayback Pharma (2023), Covis Group (2025), and Sebela's Bowel Prep Franchise (2025), each adding therapeutic-area depth, geographic reach, and development capacity. The company is backed by private equity sponsor QHP Capital, which closed a $1.1 billion single-asset continuation vehicle in February 2026 to fund continued organic growth and further M&A. As of 2025 the company operated nine offices across the US, Canada, Ireland, Switzerland, and India, including three R&D sites in Hyderabad.

Name

Azurity Pharmaceuticals

Legal name

Azurity Pharmaceuticals, Inc.

Website

https://azurity.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Azurity Pharmaceuticals is a privately held specialty pharma company that develops dose-form innovations — primarily ready-to-use oral liquids, suspensions, and injectables — of established medicines through the 505(b)(2) regulatory pathway, serving patients with swallowing difficulties and other unmet needs across 10 therapeutic areas in 50+ countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Specialty pharmaceuticals
• Dose-form innovation
• Branded pharmaceuticals
• Oral liquid formulations
• 505(b)(2) pathway

Headquarters

HQ city

Woburn

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Revenue from sales of branded pharmaceutical products across 10 therapeutic areas and 10 dosage forms in over 50 countries.
2. Licensing and Commercialization Rights: Exclusive licensing agreements for commercialization rights with milestone and royalty payments, such as WIDAPLIK partnership with George Medicines.
3. Generic Drug Competition: Faces generic competition for branded drugs like Edarbi, with Lupin launching generic version with 180-day exclusivity.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Azurity Pharmaceuticals develops and commercializes specialty pharmaceutical products, with a focus on dose-form innovations such as ready-to-use oral liquid, suspension, and injectable formulations of established medicines for patients who have difficulty swallowing tablets or capsules. The company operates a portfolio of 50+ medicines across 10 therapeutic areas (cardiovascular, CNS, oncology, endocrinology, GI, respiratory, hematology, immunology, anti-infective, allergy) and 10 dosage forms, distributed in over 50 countries.

Product overview

Azurity Pharmaceuticals is a specialty pharmaceutical company operating a portfolio-based model with over 50 medicines across 10 therapeutic areas. The company differentiates itself through dose-form innovation, developing ready-to-use liquid formulations (oral solutions, suspensions, and injections) of established medicines for patients who have difficulty swallowing tablets or capsules. Their product portfolio includes multiple acquired brands from previous acquisitions (Arbor Pharmaceuticals, Covis Pharma, Slayback Pharma) and licensed products (WIDAPLIK from George Medicines). The portfolio spans cardiovascular medications (JAVADIN, EDARBI, EPANED, KATERZIA, QBRELIS, SOTYLIZE), central nervous system treatments (ARYNTA, EPRONTIA, FLEQSUVY, ZONISADE), endocrinology products (BRYNOVIN, AZMIRO, ADTHYZA), gastrointestinal medications (KONVOMEP, SUFLAVE, SUPREP, SUTAB), oncology drugs (DANZITEN, GLIADEL, VIVIMUSTA, XATMEP), and respiratory products (ALVESCO, DUAKLIR, TUDORZA). The company also offers diagnostic agents (FERABRIGHT as MRI contrast agent, FERAHEME for iron deficiency). The portfolio is distributed across more than 50 countries through a Next-Gen Commercial Model leveraging data, analytics, and AI-driven digital tools.

Differentiator

Problem solved

Functional benefit

Products and services

• FERABRIGHT (ferumoxytol injection) First and only FDA-approved iron-based MRI contrast agent for brain imaging in adults with known or suspected malignant neoplasms of the brain; processed through normal iron metabolism pathways offering a non-gadolinium alternative.
• JAVADIN (clonidine hydrochloride) Oral Solution First and only FDA-approved immediate-release ready-to-use oral liquid clonidine formulation for treating hypertension in adult patients who have difficulty swallowing tablets.
• ARYNTA (lisdexamfetamine dimesylate) Oral Solution Ready-to-use oral solution for ADHD treatment in adults and pediatric patients 6 years and older, stored at room temperature; provides a liquid alternative for patients who have difficulty swallowing capsules.
• XIFYRM (meloxicam injection) IV NSAID injection for managing moderate-to-severe pain in adults, offering once daily dosing.
• BRYNOVIN (sitagliptin) Oral Solution First and only oral liquid sitagliptin, a DPP-4 inhibitor indicated as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.
• DANZITEN (nilotinib) tablets First and only nilotinib formulation with no mealtime restrictions for treating chronic myeloid leukemia in adults.
• AZMIRO (testosterone cypionate) injection First and only FDA-approved prefilled testosterone cypionate injection for testosterone replacement therapy in males.
• NYMALIZE (nimodipine) Oral Solution Prefilled Syringe Oral solution formulation for treating neurological complications from subarachnoid hemorrhage, available in prefilled ENFit syringes.
• EPANED (enalapril maleate) Oral Solution Oral solution formulation of ACE inhibitor for treating hypertension and heart failure in patients who have difficulty swallowing tablets.
• KATERZIA (amlodipine) Oral Suspension Oral suspension formulation of calcium channel blocker for treating hypertension in patients who have difficulty swallowing tablets.
• QBRELIS (lisinopril) Oral Solution Oral solution formulation of ACE inhibitor for treating hypertension in patients who have difficulty swallowing tablets.
• SOTYLIZE (sotalol hydrochloride) Oral Solution Oral solution formulation of antiarrhythmic agent for treating life-threatening ventricular arrhythmias and atrial fibrillation.
• WIDAPLIK (telmisartan, amlodipine and indapamide) First and only FDA-approved triple-combination hypertension medication combining telmisartan, amlodipine, and indapamide, including two doses lower than currently available single-pill combinations. Licensed from George Medicines.
• EDARBI (azilsartan medoxomil) Angiotensin II receptor blocker indicated for treating hypertension in adults.
• EDARBYCLOR (azilsartan medoxomil/chlorthalidone) Combination angiotensin receptor blocker and diuretic for treating hypertension.
• EPRONTIA (topiramate) Oral Solution First and only FDA-approved ready-to-use liquid topiramate formulation for treating seizures and migraine headaches in patients who have difficulty swallowing tablets.
• FLEQSUVY (baclofen) Oral Suspension Oral suspension formulation of muscle relaxant for treating spasticity in patients with multiple sclerosis and spinal cord injuries.
• ZONISADE (zonisamide) Oral Suspension Oral suspension formulation of anticonvulsant for treating seizures in patients who have difficulty swallowing tablets.
• MYHIBBIN (mycophenolate mofetil) Oral Suspension
• KONVOMEP (omeprazole and sodium bicarbonate) Oral Suspension Oral suspension formulation combining proton pump inhibitor and antacid for treating acid reflux and ulcers.
• SUFLAVE (PEG/electrolytes) Bowel preparation oral solution for colonoscopy procedures.
• SUTAB (sodium/magnesium/potassium sulfates) Tablet-based bowel preparation for colonoscopy procedures.
• FERAHEME (ferumoxytol injection) IV iron replacement therapy indicated for treating iron deficiency anemia in adults intolerant to oral iron or with unsatisfactory response, and in adults with chronic kidney disease.
• GLIADEL Wafer (carmustine implant) Implantable wafer containing chemotherapy agent for treating certain brain tumors.
• VIVIMUSTA (bendamustine hydrochloride) Injection formulation of alkylating agent for treating chronic lymphocytic leukemia and non-Hodgkin lymphoma.
• XATMEP (methotrexate) Oral Solution Oral solution formulation of antimetabolite for treating certain cancers and autoimmune conditions.
• ALVESCO (ciclesonide) Inhalation aerosol corticosteroid for treating asthma.
• DUAKLIR PRESSAIR (aclidinium/formoterol) Combination long-acting muscarinic antagonist and beta-agonist inhalation powder for COPD maintenance.
• TUDORZA PRESSAIR (aclidinium bromide) Long-acting muscarinic antagonist inhalation powder for COPD maintenance.
• FIRVANQ (vancomycin hydrochloride) Oral Solution Oral solution antibiotic for treating Clostridioides difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus.
• ADTHYZA (thyroid tablets) Thyroid hormone replacement therapy for treating hypothyroidism.

Quantifiable outcome

• Arynta demonstrated symptom control for up to 13 hours in children and up to 14 hours in adults in Phase 3 clinical trials
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered major and minor.

• ACA PharmamajorChannel Partner/ Reseller/ Distributor · 21 May 2026ACA Pharma and Azurity announced approval of Feraheme and Ferabright in Macau. ACA Pharma serves as exclusive distributor for ferumoxytol-based products across Macau, Hong Kong, Singapore, Greater Bay Area and Mainland China.
• Sebela PharmaceuticalsmajorStrategic or Co-development Partner · 17 November 2025Azurity acquired Sebela's Bowel Prep Franchise including two leading bowel preparation therapies for colonoscopies, strengthening Azurity's gastrointestinal portfolio. Over 50 colleagues from Sebela's commercial and support teams joined Azurity.
• Ogilvy HealthmajorGTM or Marketing Partner · 12 November 2025Azurity named Ogilvy Health as its public relations and marketing agency of record as part of broader brand evolution following rapid growth. Partnership aims to enhance external visibility and drive strategic brand repositioning.
• George MedicinesmajorOEM/ Whitelabel/ Licensing Partner · 21 July 2025George Medicines signed exclusive licensing and supply agreement with Azurity for commercialization of WIDAPLIK in the United States. WIDAPLIK is the first and only FDA-approved triple-combination hypertension medication.
• Eversheds SutherlandminorImplementation/ SI/ Consulting Partner · 19 March 2025Eversheds Sutherland advised Azurity Pharmaceuticals on strategic acquisition of Covis Pharma Group.
• Covis PharmamajorStrategic or Co-development Partner · 14 March 2025Azurity completed acquisition of Covis Group S.à r.l., making Covis a wholly-owned subsidiary. The acquisition enhances Azurity's therapeutic portfolio, global reach, and development capabilities.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Padagis: Padagis (formerly Perrigo's generics business) specializes in specialty generics and OTC pharmaceutical products, with a portfolio spanning multiple therapeutic areas — comparable in scale and therapeutic breadth to Azurity's specialty pharma platform.
• ANI Pharmaceuticals: ANI Pharmaceuticals is a specialty pharma company focused on acquiring, developing, and commercializing branded and generic prescription pharmaceuticals, including oral liquids and niche dosage forms — directly comparable to Azurity's model of reformulating established molecules for underserved patient segments.
• Amneal Pharmaceuticals: Amneal combines specialty branded pharmaceuticals with a generics business, including injectables and complex formulations — closely comparable to Azurity's hybrid specialty/innovation model.
• Mallinckrodt Pharmaceuticals: Mallinckrodt is a specialty pharmaceutical company with a diversified portfolio across multiple therapeutic areas including CNS, autoimmune, and rare diseases; comparable to Azurity in its specialty brand focus and history of acquiring established franchises.
• Endo International: Endo operates a specialty pharmaceutical business with branded and generic sterile injectables, including differentiated formulations — comparable to Azurity's specialty branded portfolio and dose-form innovation approach.
• Upsher-Smith Laboratories: Upsher-Smith is a privately held specialty pharmaceutical company that develops, manufactures, and markets branded and generic products including dose-form innovations — highly comparable to Azurity's specialty dose-form innovation focus.
• Lupin Pharmaceuticals: Lupin is a global pharmaceutical company with a specialty and generics portfolio; directly comparable to Azurity as it has launched generic competition (azilsartan) against Azurity's Edarbi franchise and competes in overlapping therapeutic areas.

Broad incumbents

• Bausch Health: Bausch Health is a diversified pharmaceutical company with branded specialty, generics, and consumer health segments; comparable as a larger incumbent operating across the same therapeutic categories (GI, neurology, dermatology) as Azurity.
• Hikma Pharmaceuticals: Hikma is a global specialty pharmaceutical company with branded and generic injectable and oral products across cardiovascular, CNS, and other therapeutic areas — overlapping with Azurity's specialty injectable and oral dose-form portfolio.

Others

• Covis Pharma: Covis Pharma is now a wholly-owned subsidiary of Azurity following the March 2025 acquisition; pre-acquisition it was a comparable specialty pharma peer focused on branded therapeutics for chronic conditions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/cutispharma-inc.
• Xx.com/azuritypharma

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Azurity Pharmaceuticals